COMPASS Pathways (NASDAQ:CMPS - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect COMPASS Pathways to post earnings of ($0.47) per share for the quarter.
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
COMPASS Pathways Trading Up 2.2 %
Shares of COMPASS Pathways stock traded up $0.09 during trading on Friday, hitting $4.19. The company's stock had a trading volume of 630,372 shares, compared to its average volume of 798,868. The stock has a market cap of $388.30 million, a price-to-earnings ratio of -1.90 and a beta of 2.34. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a 52 week low of $2.49 and a 52 week high of $9.63. The stock has a 50-day moving average price of $3.34 and a two-hundred day moving average price of $4.11.
Wall Street Analyst Weigh In
CMPS has been the topic of a number of recent analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Stifel Nicolaus initiated coverage on COMPASS Pathways in a research report on Thursday, February 27th. They set a "buy" rating and a $11.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a report on Tuesday, March 4th. Cantor Fitzgerald reiterated an "overweight" rating on shares of COMPASS Pathways in a report on Friday, March 28th. Finally, Canaccord Genuity Group dropped their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $20.20.
View Our Latest Stock Report on COMPASS Pathways
COMPASS Pathways Company Profile
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Further Reading
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
